IRD

Opus Genetics, Inc. IRD

IRD
Opus Genetics, Inc. IMDX
Insight Molecular Diagnostics Inc. TCRX
TScan Therapeutics, Inc. NAUT
Nautilus Biotechnology, Inc. SRZN
Surrozen, Inc. SEER
Seer, Inc. INO
Inovio Pharmaceuticals, Inc. ZNTL
Zentalis Pharmaceuticals, Inc. AGEN
Agenus Inc. VTGN
VistaGen Therapeutics, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode IRD IMDX TCRX NAUT SRZN SEER INO ZNTL AGEN VTGN
6M 136.85 % 92.73 % 44.38 % 77.22 % 37.09 % 17.26 % 24.60 % 19.58 % 53.33 % 83.33 %
YTD 57.94 % 184.55 % -25.24 % -27.81 % -3.51 % -0.86 % 28.02 % -43.00 % 33.98 % 22.59 %
1Y 47.41 % 113.87 % -52.76 % -56.58 % 41.75 % 19.07 % -58.91 % -39.58 % -6.12 % 34.32 %
3Y 54.26 % -57.50 % -24.51 % -45.29 % -59.44 % -68.57 % -90.14 % -92.93 % -92.07 % 23.33 %
5Y 54.26 % -78.61 % -78.00 % -87.97 % -90.93 % -95.91 % -98.14 % -95.74 % -94.33 % -80.89 %
10Y 54.26 % -95.90 % -78.00 % -88.31 % -90.93 % -95.91 % -97.04 % -92.63 % -95.85 % -98.30 %
From the beginning 54.26 % -95.90 % -78.00 % -88.31 % -90.93 % -95.91 % -99.67 % -92.63 % -99.94 % -99.72 %

Dividend

Inovio Pharmaceuticals, Inc.